Mayur Parmar | Senior Drug Inspector
Gujarat FDA | India

Mayur Parmar, Senior Drug Inspector, Gujarat FDA

Mr. Mayur Parmar is working as Drugs Inspector in Food and Drugs Control Administration, Ministry of health and family welfare, Govt. Of Gujarat. He is carrying five years of rich experience and during his tenure he has inspected various Drug manufacturing sites, drugs Distribution sites, hospitals, blood banks and blood storage centres as per Indian as well as WHO guidelines. With five years of experience of Drug Regulation, Mayur has investigated more than 125 NSQ drugs and launched Prosecution for spurious and misbranded drugs. Prior to it Mayur has completed his M.Pharm with specialization in New Drug Delivery System from Maharaja Sayajirao university of Baroda, Gujarat with two gold medals for securing first rank in the university. He was honoured for Excellence in Academic Carrier at BIPAAS Alumni. He has published four research papers in International and National journals. His views on Pharma regulations have been published in various magazines like eHealth and others. He is pursuing his Ph.D in New Drug Delivery System. He is a Member of WHO team for up gradation of National Regulatory system. He has chaired two international conferences and speaked at various national and international forums. He is having industrial experience in formulation development and Intellectual property management. Apart from it, He is actively involved in the various social activities for welfare of underprivileged through “REASON FOR SMILE” organization. A Huge believer of lifetime learning - Mayur constantly strives to improve himself, both on personal and professional front.

Appearances:



Conference Day 2 @ 13:30

Ensuring uniformity of GMP inspections in biologics manufacturing

Countries across the globe are concerned about the safety and efficacy of the drugs supplied. As India expands its biologics supply globally, there is an increased emphasis in ensuring uniformity in inspection requirements for drugs manufactured in India. This panel discusses how global regulators such as US FDA, EMA can work closer together with CDSCO in ensuring uniformity in GMP inspections.
  • Overview of India’s inspection landscape and updates
  • Understanding the differences and overlaps in current standards
  • Exploring ways for various regulators to work closer together, including more combined inspections for newly recruited CDSCO inspectors

back to speakers